United Kingdom

People: Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

6:05pm BST
Change (% chg)

$4.69 (+2.06%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rowinsky, Eric 

Dr. Eric K. Rowinsky, M.D. is an Independent Director of Biogen Inc. Dr. Rowinsky has served as one of our directors since 2010. He has served as President of RGenix, Inc., a privately-held life sciences company, since November 2015 and as its Executive Chairman since December 2015. From January 2012 to November 2015 Dr. Rowinsky was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells. Dr. Rowinsky is an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009 he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004 Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at The Johns Hopkins University School of Medicine and on the staff of the Johns Hopkins Hospital. Dr. Rowinsky serves as a director of Fortress Biotech Inc., a biopharmaceutical company, and Verastem, Inc., a biopharmaceutical company, and Biophytis, a biotechnology company. Dr. Rowinsky has extensive research and drug development experience and broad scientific and medical knowledge.

Basic Compensation

Total Annual Compensation, USD 149,500
Restricted Stock Award, USD 269,479
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 418,979

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --